vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics (Nasdaq: VTVT) granted 2,500 stock options to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) granted 2,500 stock options to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.48 per share, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting quarterly over the next 36 months, subject to continued employment.

The grant is made under the company’s 2026 Inducement Plan. vTv is a late-stage biopharmaceutical company whose clinical pipeline is led by cadisegliatin (TTP399), an oral glucokinase activator in a US Phase 3 trial for type 1 diabetes and granted FDA Breakthrough Therapy designation.

Argus Aug 20 session 5 alerts

+0.56% close to close 0.6x rel. volume Open Argus

Details

News Market Reaction – VTVT

$131.86M Market Cap

On Aug 20, the first trading day after this news, VTVT closed 0.56% above the previous close. Our momentum scanner recorded 5 alerts in the available session data.

Data tracked by StockTitan Argus for the Aug 20 session.

Key Figures

Stock Options: 2,500 options Exercise Price: $31.48 per share Initial Vesting: 25% +4 more

Stock Options

2,500 options

Inducement grant to a non-executive employee

Exercise Price

$31.48 per share

Exercise price for the granted options

Initial Vesting

25%

Vests on the one-year anniversary

Vesting Period

4 years

Total vesting period for the option award

Remaining Vesting

36 months

Quarterly vesting after the first anniversary

Option Term

10 years

Term of the granted options

Trial Phase

Phase 3

Cadisegliatin trial in type 1 diabetes

Historical Context

5 past events · Latest: Aug 06

5 events

1. Aug 06

   Second-quarter earnings

   24h Move

   +0.6%

   Results included cash funding expectations through anticipated Phase 3 topline data.

2. Jul 28

   Inducement option grant

   24h Move

   +1.3%

   Two employees received 23,500 options with four-year vesting and ten-year terms.

3. Jul 02

   Inducement option grant

   24h Move

   -2.4%

   Two employees received 12,500 options under the 2026 Inducement Plan.

4. Jun 02

   Inducement option grant

   24h Move

   -0.2%

   A new employee received 2,500 options at a $34.30 exercise price.

5. May 13

   First-quarter earnings

   24h Move

   +21.4%

   Revenue and net income included a $20 million upfront license payment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), glucokinase activator, breakthrough therapy designation, adjunctive therapy

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

glucokinase activator medical

"a potential first-in-class oral glucokinase activator being investigated"

A glucokinase activator is a drug that boosts the activity of glucokinase, an enzyme that helps the liver and pancreas sense and lower blood sugar. Think of it as turning up the sensitivity of the body’s sugar thermostat so insulin release and sugar storage respond more effectively; for investors, these drugs matter because they can become new diabetes treatments with sizable market potential while carrying typical development, safety and regulatory risks that affect a company’s value.

breakthrough therapy designation regulatory

"Cadisegliatin has been granted Breakthrough Therapy designation"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

adjunctive therapy medical

"a novel, potential first-in-class oral adjunctive therapy to insulin"

Adjunctive therapy is a treatment given in addition to a primary therapy to boost its effectiveness, reduce side effects, or treat related symptoms — like adding a side dish to make a main meal work better. For investors, evidence that an adjunctive therapy improves outcomes, safety, or convenience can expand a product’s use, support stronger regulatory labeling and reimbursement, and increase commercial potential by reaching more patients or strengthening a therapy’s market position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted at an exercise price of $31.48 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock options did vTv Therapeutics (VTVT) grant on August 19, 2026?

vTv Therapeutics granted 2,500 inducement stock options to a non-executive employee on August 19, 2026. According to vTv Therapeutics, the options have a $31.48 exercise price, 10-year term, and four-year vesting schedule, with 25% after one year and the rest vesting quarterly.

How do the vTv Therapeutics (VTVT) inducement options under Nasdaq Rule 5635(c)(4) vest?

The vTv Therapeutics inducement options vest over four years under Nasdaq Rule 5635(c)(4). According to vTv Therapeutics, 25% vests on the one-year anniversary of the vesting commencement date, and the remaining shares vest quarterly over the following 36 months, subject to continued employment.

What is the exercise price and term of the vTv Therapeutics (VTVT) August 2026 inducement options?

The inducement options have an exercise price of $31.48 per share and a 10-year term. According to vTv Therapeutics, these options were granted under the 2026 Inducement Plan as a material inducement to employment for a non-executive employee.

What is cadisegliatin (TTP399) in vTv Therapeutics’ (VTVT) pipeline?

Cadisegliatin (TTP399) is an oral, liver-selective glucokinase activator in a US Phase 3 trial. According to vTv Therapeutics, it is being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes and has FDA Breakthrough Therapy designation.

Has cadisegliatin from vTv Therapeutics (VTVT) been proven safe and effective or received FDA approval?

Cadisegliatin has not yet been proven safe and effective or received FDA approval. According to vTv Therapeutics, it remains under investigation, and there is no guarantee it will obtain health authority approval or become commercially available for the use being studied.